Explore

Rapid Read Rapid Read
Ketamine's Role in Depression Treatment Explored by Yale's Dr. John Krystal

Ketamine's Role in Depression Treatment Explored by Yale's Dr. John Krystal

Dr. John Krystal of Yale University has been at the forefront of research into the use of ketamine for treating depression. Ketamine, traditionally an anesthetic, has shown rapid antidepressant effects, particularly in treatment-resistant cases. Dr. Krystal's work has demonstrated that ketamine can trigger the release of brain-derived neurotrophic factor (BDNF), promoting synaptic growth and resilience against stress. This discovery has led to the FDA approval of esketamine, a derivative of ketamine, for treatment-resistant depression. The treatment is administered in clinical settings to ensure safety and prevent misuse, as ketamine has potential for abuse.
Rapid Read Rapid Read
Exploring Treatment Options for Treatment-Resistant Depression

Exploring Treatment Options for Treatment-Resistant Depression

Treatment-resistant depression remains a significant challenge, prompting the exploration of various therapeutic options. These include esketamine nasal spray, transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT). Esketamine is FDA-approved for adults who have not responded to at least two oral antidepressants, while TMS uses magnetic pulses to stimulate mood-regulating brain regions without anesthesia. ECT, a more established treatment, involves controlled electrical stimulation under anesthesia. Each option offers different benefits and is considered based on individual patient needs and previous treatment responses.
Rapid Read Rapid Read
Desvenlafaxine Offers Flexible Dosing for Depression Patients

Desvenlafaxine Offers Flexible Dosing for Depression Patients

Desvenlafaxine, marketed as Pristiq, can be taken with or without food, providing flexibility for patients managing their daily routines. The medication is an extended-release tablet that must be swallowed whole to maintain its efficacy. While nausea is a common side effect during the initial weeks of treatment, it typically subsides. The FDA-approved labeling confirms that food does not significantly affect the drug's absorption, allowing patients to integrate it into their schedules without dietary restrictions.
Reuters Reuters
Eli Lilly to offer early access to next-gen obesity drug to some patients

Eli Lilly to offer early access to next-gen obesity drug to some patients

By Sneha S K and Deena Beasley Aug 3 (Reuters) - Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its U.S. FDA approval.
Rapid Read Rapid Read
FDA Expands Approval for Pluvicto, Doubling Eligible Prostate Cancer Patients

FDA Expands Approval for Pluvicto, Doubling Eligible Prostate Cancer Patients

The FDA has expanded the approval of Pluvicto, a radioligand therapy, for use in men with metastatic prostate cancer that still responds to hormone therapy. This decision nearly doubles the number of patients eligible for the treatment. Pluvicto, which is administered at licensed facilities, is combined with an androgen receptor pathway inhibitor. The approval is based on a Phase III trial showing a 28% reduction in disease progression risk. However, the therapy's availability is limited to centers with the necessary radioactive materials license.
Trendline Trendline
CRISPR Therapeutics Reports Progress in Gene-Edited Therapies

CRISPR Therapeutics Reports Progress in Gene-Edited Therapies

CRISPR Therapeutics Reports Progress in Gene-Edited Therapies
Rapid Read Rapid Read
FDA Panel Supports Peptide Therapies Amid Regulatory Uncertainty

FDA Panel Supports Peptide Therapies Amid Regulatory Uncertainty

A panel advising the Food and Drug Administration (FDA) has voted to support the production of six out of seven peptide therapies, despite concerns from FDA scientists. These peptides, including BPC-157 and TB-500, are popular in wellness circles for their potential benefits in injury recovery and muscle growth. However, they remain illegal for U.S. pharmacies to produce. The FDA must now decide whether to allow compounding pharmacies to manufacture these peptides, a decision that could significantly impact their availability and regulation.
Rapid Read Rapid Read
Revisiting Freud: A New Perspective on Psychoanalysis and Psychiatry

Revisiting Freud: A New Perspective on Psychoanalysis and Psychiatry

A recent article explores the resurgence of interest in Freudian psychoanalysis amidst ongoing debates in the field of psychiatry. Despite being largely dismissed in favor of biological psychiatry, Freudian concepts continue to influence cultural and psychological discussions. The article highlights the work of neuroscientist Mark Solms, who advocates for integrating Freudian theories with modern neuroscience. Solms argues that psychoanalysis offers valuable insights into mental health treatment, challenging the dominance of pharmacological approaches. The discussion is set against a backdrop of criticism towards biological psychiatry's limited success in addressing mental health issues.
Rapid Read Rapid Read
Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide

Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide

Eli Lilly has announced that it will allow more patients to apply for special access to retatrutide, an unapproved obesity drug, following requests from doctors. This decision comes after the company granted a single patient access to the drug, prompting inquiries from healthcare providers. Lilly's move marks a shift in its approach to the drug's availability, aligning with FDA guidance for expanded access to investigational treatments.
Rapid Read Rapid Read
Study Links Ketamine Treatment to Increased Morning Cortisol in Depressed Patients

Study Links Ketamine Treatment to Increased Morning Cortisol in Depressed Patients

A recent clinical trial has revealed that a single dose of ketamine can increase morning cortisol levels in patients suffering from major depression and suicidal thoughts. Published in the Journal of Affective Disorders, the study found that this hormonal increase persists for at least 24 hours post-treatment. The research aimed to explore the stress hormone system as a potential biomarker for ketamine's therapeutic effects. Cortisol, a hormone produced by the adrenal glands, helps manage stress and typically peaks in the morning. The study involved 80 adults with major depressive disorder, who were randomly assigned to receive either ketamine or midazolam. Saliva samples were collected to measure cortisol levels before and after treatment. Results showed a significant increase in morning cortisol levels in the ketamine group, suggesting a link between ketamine treatment and the body's stress response system.
Rapid Read Rapid Read
Israeli Biological Therapy Shows Promise in Alzheimer's Treatment

Israeli Biological Therapy Shows Promise in Alzheimer's Treatment

An Israeli-developed biological therapy aimed at restoring the immune system's ability to protect the brain has demonstrated a favorable safety profile in its first human trial. The therapy, known as IBC-Ab002, is based on research by Professor Michal Schwartz from the Weizmann Institute of Science. Unlike most Alzheimer's treatments that target amyloid plaques, IBC-Ab002 focuses on restoring immune functions that decline with age. The trial involved 40 patients with early-stage Alzheimer's disease across medical centers in the UK, Israel, and the Netherlands. Results showed the treatment was safe and well-tolerated, with biological activity matching its design and reducing biomarkers associated with neuronal damage.
Rapid Read Rapid Read
Ketamine's Impact on Cortisol Levels Linked to Rapid Relief of Suicidal Thoughts

Ketamine's Impact on Cortisol Levels Linked to Rapid Relief of Suicidal Thoughts

A clinical trial has found that a single dose of ketamine increases morning cortisol levels in patients with major depression and suicidal thoughts. This hormonal boost persists for at least 24 hours and may be linked to ketamine's rapid antidepressant effects. The study involved 80 adults and used saliva samples to measure cortisol levels before and after ketamine administration. The findings suggest that ketamine's impact on the body's stress response system could play a role in reducing suicidal ideation.